Media coverage about Revance Therapeutics (NASDAQ:RVNC) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Revance Therapeutics earned a news impact score of 0.17 on Accern’s scale. Accern also assigned news coverage about the biopharmaceutical company an impact score of 45.7544744672015 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the media stories that may have impacted Accern’s rankings:
- Revance Therapeutics (RVNC) Cut to Hold at Guggenheim (americanbankingnews.com)
- Revance Therapeutics (RVNC) Presents At Needham And Company 17th Annual Healthcare Conference – Slideshow (seekingalpha.com)
- Revance Therapeutics Inc (RVNC) Receives Consensus Recommendation of “Buy” from Brokerages (americanbankingnews.com)
- Revance Therapeutics (RVNC) Now Covered by Analysts at Needham & Company LLC (americanbankingnews.com)
- Revance to Host Investor Day on April 19, 2018 (finance.yahoo.com)
Several equities analysts have recently issued reports on the stock. Piper Jaffray set a $48.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a report on Thursday, March 1st. ValuEngine lowered shares of Revance Therapeutics from a “hold” rating to a “sell” rating in a report on Monday, December 4th. Zacks Investment Research raised shares of Revance Therapeutics from a “sell” rating to a “hold” rating in a report on Tuesday, March 6th. Cowen set a $55.00 price target on shares of Revance Therapeutics and gave the company a “buy” rating in a report on Wednesday, January 17th. Finally, Mizuho reissued a “buy” rating and issued a $54.00 price target on shares of Revance Therapeutics in a report on Friday, January 5th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and eleven have issued a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus price target of $45.17.
Revance Therapeutics (NASDAQ:RVNC) last announced its earnings results on Wednesday, February 28th. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.99) by ($0.15). The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.09 million. Revance Therapeutics had a negative return on equity of 64.40% and a negative net margin of 46,025.57%. Revance Therapeutics’s revenue for the quarter was down 50.7% on a year-over-year basis. During the same period in the previous year, the company posted ($0.95) earnings per share. analysts predict that Revance Therapeutics will post -3.56 earnings per share for the current year.
In related news, CFO Lauren P. Silvernail sold 3,431 shares of the company’s stock in a transaction on Thursday, March 22nd. The shares were sold at an average price of $30.85, for a total value of $105,846.35. Following the completion of the transaction, the chief financial officer now directly owns 68,371 shares of the company’s stock, valued at approximately $2,109,245.35. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Phyllis Gardner sold 5,333 shares of the company’s stock in a transaction on Friday, March 16th. The stock was sold at an average price of $31.51, for a total transaction of $168,042.83. Following the completion of the transaction, the director now directly owns 5,250 shares of the company’s stock, valued at $165,427.50. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 98,366 shares of company stock valued at $3,182,947. Company insiders own 18.86% of the company’s stock.
COPYRIGHT VIOLATION NOTICE: This news story was originally reported by BBNS and is the sole property of of BBNS. If you are accessing this news story on another domain, it was stolen and republished in violation of US and international trademark & copyright law. The original version of this news story can be accessed at https://baseballnewssource.com/2018/03/30/somewhat-favorable-press-coverage-somewhat-unlikely-to-affect-revance-therapeutics-rvnc-share-price/1973542.html.
About Revance Therapeutics
Revance Therapeutics, Inc is a clinical-stage biotechnology company. The Company is focused on the development, manufacturing and commercialization of botulinum toxin products for multiple aesthetic and therapeutic indications. Its peptide technology enables delivery of botulinum toxin type A through two investigational drug product candidates, DaxibotulinumtoxinA for Injection (RT002), or RT002 injectable, and DaxibotulinumtoxinA Topical Gel (RT001), or RT001 topical.
Receive News & Ratings for Revance Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Revance Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.